- Chronic myeloid leukemia:
- Newly diagnosed Ph+ chronic phase (CP):
- Adults: PO 300mg BD
- Adults: PO 300mg BD
- Newly diagnosed Ph+ chronic phase (CP):
-
- CP and accelerated phase (AP) Ph+ CML in patients resistant to or intolerant to prior therapy that included imatinib:
- Adults: PO 400mg BD
- Adults: PO 400mg BD
- CP and accelerated phase (AP) Ph+ CML in patients resistant to or intolerant to prior therapy that included imatinib:
-
- Children >1 year (Based on body surface area):
- ≤0.32m2: 50mg/dose. Max: 100mg
- 0.33-0.54m2: 100mg/dose; Max: 200mg
- 0.55-0.76m2: 150mg/dose; Max: 300mg
- 0.77-0.97m2: 200mg/dose; Max: 400mg
- 0.98-1.19m2: 250mg/dose; Max: 500mg
- 1.2-1.41m2: 300mg/dose; Max: 600mg
- 1.42-1.63m2: 350mg/dose; Max: 700mg
- ≥1.64m2: 400mg/dose; Max: 800 mg
- Children >1 year (Based on body surface area):
- Capsule:
- 150mg
- 200mg
- Taken twice daily at 12-hour intervals (unless dosage modification required)
- Administer on empty stomach; do not consume food for at least 2 before the dose and for at least 1 hr after the dose is taken
Tyrosine kinase inhibitors anticancer
It selectively binds with high affinity to ATP-binding site of BCR-ABL kinase inhibiting cell proliferation in cell lines and in primary Ph+ CML leukemia cells. It is also active against imatinib-resistant mutant forms of Bcr-Abl
- Rash
- Headache
- Nausea
- Fatigue
- Pruritus
- Diarrhea
- URI
- Arthralgia
- Constipation
- Cough
- Vomiting
- Fever
- Pain
- Asthenia
- Muscle spasms
- Dyspnea
- Peripheral edema
- Alopecia
- Night sweats
- Decreased appetite
- Dyspepsia
- Insomnia
- Hypertension
- Influenza
- Xeroderma
- Dizziness
- Gastroenteritis
- Thrombocytopenia
- Neutropenia
- Hypersensitivity to class/components
- Hypokalemia
- Hypomagnesemia
- QT prolongation
- Congenital long QT syndrome
- Pregnancy
WARNING:
Prolonged QT interval and sudden death reported
- Arsenic trioxide
- Cisapride
- Disopyramide
- Goserelin
- Ibutilide
- Indapamide
- Leuprolide
- Levoketoconazole
- Pentamidine
- Pimozide
- Procainamide
- Quinidine
- Sotalol
- Toremifene
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated and for at least 14 days after discontinuation of drug |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Nilonix | 150mg | Capsule | 120’s | Beacon Medicare | Generics Africa |
| Nilonix | 200mg | Capsule | 120’s | Beacon Medicare | Generics Africa |
| Tasigna | 200mg | Capsule | 28’s | Novartis Pharma | Novartis Kenya |
| Tasigna | 150mg | Capsule | 28’s | Novartis Pharma | Novartis Kenya |